Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Advaxis' listeria cancer vaccine receives regulatory approval for phase I/II testing
March 23rd, 2006
Advaxis, Inc., (ADXS) announced that regulators have allowed the company to initiate phase I/II clinical testing with its lead compound, listeria-based cancer vaccine, Lovaxin C. Lovaxin C, which specifically targets cervical cancer in women, will be tested for the first time in humans in this study. Roni Appel, president and CEO of Advaxis said: "This day marks a pivotal day for Advaxis as our first cancer immunotherapeutic enters the clinic." Preclinical data for Lovaxin C demonstrates an extremely robust immune response to tumors upon administration of the drug and eradication of tumors in more than half of the animals...
Source: Women's Health Weekly (2006-03-23)
|
